On the Concept of Harmonization of the Pharmacopoeias of the Member States of the Eurasian Economic Union
Decision of the Board of the Eurasian Economic Commission No. 119 dated September 22, 2015
In accordance with Article 5 of the Agreement on Common Principles and Rules for the Circulation of Medicinal Products within the Eurasian Economic Union dated December 23, 2014, paragraph 27 of Annex No. 2 to the Rules of Procedure of the Eurasian Economic Commission, approved by Decision No. 98 of the Supreme Eurasian Economic Council dated December 23, 2014, and Decision No. 108 of the Supreme Eurasian Economic Council dated December 23, 2014, “On the Implementation of the Agreement on Common Principles and Rules for the Circulation of Medicinal Products within the Eurasian Economic Union”, the Board of the Eurasian Economic Commission decided:
- To approve the attached Concept for Harmonization of the Pharmacopoeias of the Member States of the Eurasian Economic Union.
- This Decision shall enter into force on the date of entry into force of the Agreement on Common Principles and Rules for the Circulation of Medicinal Products within the Eurasian Economic Union dated December 23, 2014.
Chairman of the Boardof the Eurasian Economic Commission V. Khristenko
APPROVEDby Decision No. 119 of the Board of the Eurasian Economic Commissiondated September 22, 2015
CONCEPT FOR HARMONIZATION OF THE PHARMACOPOEIAS OF THE MEMBER STATES OF THE EURASIAN ECONOMIC UNION
I. Introduction
Harmonization of requirements for medicinal products is a necessary process under the conditions of the functioning of the common market for medicinal products within the Eurasian Economic Union (hereinafter referred to as the Union). At the current stage of regulation of the common market, harmonization is one of the means of developing the pharmacopoeial standards of the Member States of the Union (hereinafter referred to as the Member States).
This Concept has been developed in accordance with Article 30 of the Treaty on the Eurasian Economic Union dated May 29, 2014, Article 5 of the Agreement on Common Principles and Rules for the Circulation of Medicinal Products within the Eurasian Economic Union dated December 23, 2014, and Decision No. 108 of the Supreme Eurasian Economic Council dated December 23, 2014, “On the Implementation of the Agreement on Common Principles and Rules for the Circulation of Medicinal Products within the Eurasian Economic Union”.
This Concept defines the model and principles for the development of the Pharmacopoeia of the Eurasian Economic Union (hereinafter referred to as the Pharmacopoeia of the Union) on the basis of the pharmacopoeias of the Member States and the principal pharmacopoeias, the approval by the Pharmacopoeial Committee of the Eurasian Economic Union (hereinafter referred to as the Pharmacopoeial Committee of the Union) of harmonized pharmacopoeial articles (monographs) of the Pharmacopoeia of the Union, which are pharmacopoeial articles (monographs) jointly prepared by specialists from the Member States and approved in accordance with the established procedure by the Pharmacopoeial Committee of the Union, and the approval of the Pharmacopoeia of the Union by the Board of the Eurasian Economic Commission, with the aim of establishing transparency of all procedures in this area, as well as ensuring continuity in the process of developing new harmonized pharmacopoeial articles (monographs).
The Concept covers issues relating to the harmonization of the pharmacopoeias of the Member States both with regard to medicinal products for human use and veterinary medicinal products.
For the purposes of ensuring the proper development, amendment, updating and approval of harmonized pharmacopoeial articles (monographs), this Concept establishes the principles of interaction between the Pharmacopoeial Committee of the Union and the authorized bodies of the Member States in the field of circulation of medicinal products with regard to the creation of a single Pharmacopoeia of the Union.
This Concept is aimed at achieving the following objectives:
formation of a model for harmonization of the pharmacopoeias of the Member States;
selection of the principal pharmacopoeias, taking into account the requirements of which the harmonization of the pharmacopoeias of the Member States is to be carried out, and determination of their priority levels;
ensuring the application of a uniform procedure for harmonization of the pharmacopoeias of the Member States;
ensuring the uniformity of the principles for developing pharmacopoeial articles (monographs) of the Pharmacopoeia of the Union.
II. Modern Approaches to Harmonization of the Pharmacopoeias of the Member States
The harmonization of international pharmacopoeias began in 1948, when the Secretariat of the World Health Organization (WHO) received the relevant mandate. The first volume of the first edition of the International Pharmacopoeia was published in 1951 with the aim of harmonizing requirements for the quality of pharmaceutical substances worldwide.
Since 2012, active development of the WHO standard “Good Pharmacopoeial Practices” (GPhP) has been carried out under the auspices of the WHO Expert Committee on Specifications for Pharmaceutical Preparations for the purpose of achieving harmonization at the global level.
The main objectives of the WHO standard “Good Pharmacopoeial Practices” (GPhP) are:
ensuring the quality of medicinal products at the global level through the adoption of pharmacopoeial standards;
promoting recognition of global pharmacopoeial activities;
increasing the confidence of regulatory authorities in pharmacopoeial standards for the quality of medicinal products at the global level;
strengthening cooperation among all interested parties (national and regional pharmacopoeial committees and other organizations, regulatory authorities, and representatives of the pharmaceutical industry) and reducing costs associated with the development of pharmacopoeial standards for the quality of medicinal products;
simplifying the procedure for harmonization and recognition of pharmacopoeial standards for the quality of medicinal products at the global level;
providing support to the pharmacopoeial committees of the Member States in their work on establishing harmonized pharmacopoeial standards for the quality of medicinal products.
The WHO standard “Good Pharmacopoeial Practices” (GPhP) is intended to serve as guidance for national and regional pharmacopoeial committees and other organizations in the development, publication and distribution of pharmacopoeial requirements. The principles and approaches to the development of pharmacopoeial articles (monographs) set out therein apply to:
pharmaceutical substances;
medicinal raw materials of natural origin (plant-based, animal-based);
medicinal products;
biological products;
extemporaneous medicinal products;
reference standards used for testing medicinal products.
Examples of effective efforts to harmonize pharmacopoeias include the Pharmacopoeial Discussion Group (PDG), the Harmonization Group of the Southern Common Market (MERCOSUR), etc. The Pharmacopoeial Discussion Group (PDG) directly harmonizes the requirements of the European Pharmacopoeia, the United States Pharmacopeia and the Japanese Pharmacopoeia. Within the framework of the Harmonization Group of the Southern Common Market (MERCOSUR), pharmacopoeial standards of Latin American countries – Argentina, Brazil, Paraguay and Uruguay – are harmonized.
Thus, the experience of harmonization of pharmacopoeias at the global and regional levels should appropriately be used within the framework of the process of harmonization of the pharmacopoeias of the Member States.
III. Pharmacopoeias of the Member States
In the Russian Empire, and subsequently in the USSR, state quality control of medicinal products was carried out in accordance with the standards and provisions of the State Russian Pharmacopoeia (6 editions), and, since 1925, in accordance with the standards and provisions of the State Pharmacopoeia of the USSR. The latest editions of the State Pharmacopoeia of the USSR – the 10th edition (1969) and the 11th edition (1987 – first issue, 1990 – second issue) – have retained their regulatory nature to the present day, although to a limited extent.
In order to acquire experience in developing pharmacopoeial standards, the authorized bodies of the Member States in the field of circulation of medicinal products became official observers of the European Pharmacopoeia Commission of the Council of Europe. Pharmacopoeial committees have been established and are functioning in the Republic of Belarus, the Republic of Kazakhstan and the Russian Federation.
The pharmacopoeias of the Republic of Belarus and the Republic of Kazakhstan are almost fully harmonized with the European Pharmacopoeia. The structure of most of their pharmacopoeial articles (monographs) includes a general part based on the requirements of the European Pharmacopoeia and a national part based on the requirements of the State Pharmacopoeia of the USSR and the legislation of the Republic of Belarus and the Republic of Kazakhstan, respectively.
The general part of the pharmacopoeial articles (monographs) of the Member States contains requirements for the quality of medicinal products manufactured in accordance with the Good Manufacturing Practice Rules.
The national part of the pharmacopoeial articles (monographs) of the pharmacopoeias of the Member States reflects the specific features of approaches to the quality of medicinal products in the Member States. It includes alternative methods and additional informational materials. The requirements of the national part of pharmacopoeial articles (monographs) are often more stringent than the requirements of the European pharmacopoeial articles (monographs).
1. Republic of Belarus
The provisions concerning the State Pharmacopoeia of the Republic of Belarus are contained in the Law of the Republic of Belarus No. 161-Z dated July 20, 2006, “On Medicinal Products”.
The State Pharmacopoeia of the Republic of Belarus, 1st edition, in 3 volumes, was published and put into effect in 2007–2009. The national pharmacopoeial articles (monographs) set out requirements for testing methods, the quality of medicinal products and pharmaceutical substances, reagents, containers, the preparation and quality control of extemporaneous medicinal products, the conduct of bioavailability and bioequivalence studies of generic medicinal products, the performance of statistical processing of the results of chemical experiments, the validation of testing methods, as well as general requirements for dosage forms, etc.
Since January 1, 2013, the first volume of the State Pharmacopoeia of the Republic of Belarus, 2nd edition, has been in force. It includes general pharmacopoeial articles (monographs) on analytical methods, containers, reagents, extemporaneous medicinal products, dosage forms, homeopathic medicinal products, etc. Significant work has been carried out to update pharmacopoeial articles (monographs) having national status and supplements to pharmacopoeial articles (monographs). The first volume of the State Pharmacopoeia of the Republic of Belarus, 2nd edition, is based on the requirements of the 7th edition of the European Pharmacopoeia.
Official permission to harmonize the State Pharmacopoeia of the Republic of Belarus with the requirements of the European Pharmacopoeia was granted by the European Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM).
The second volume of the State Pharmacopoeia of the Republic of Belarus, 2nd edition, will combine the pharmacopoeial articles (monographs) contained in the second and third volumes of the State Pharmacopoeia of the Republic of Belarus, 1st edition (463 pharmacopoeial articles (monographs) on pharmaceutical substances, 136 pharmacopoeial articles (monographs) on medicinal plant raw materials, including pharmacopoeial articles (monographs) having national status). The second volume of the State Pharmacopoeia of the Republic of Belarus, 2nd edition, based on the requirements of the European Pharmacopoeia (EP 8.0–8.4), is scheduled for publication and entry into force in 2015.
The tests provided for in the development of pharmacopoeial articles (monographs) are performed in laboratories certified as compliant with STB ISO/IEC 17025-2007 “General Requirements for the Competence of Testing and Calibration Laboratories”, in a laboratory compliant with the international standard ISO/IEC 17025 and having joined the Network of Official Medicines Control Laboratories of the Council of Europe (OMCL GEON), and in a laboratory that has undergone WHO prequalification and has been recognized as compliant with WHO recommendations.
In order to ensure the relevance of the State Pharmacopoeia of the Republic of Belarus, as well as the possibility of including new pharmacopoeial articles (monographs) in it that are absent from the European Pharmacopoeia, an agreement was signed with the United States Pharmacopeial Convention (USP) in November 2013, allowing texts from the United States Pharmacopeia to be borrowed for their inclusion in pharmacopoeial articles (monographs) of the State Pharmacopoeia of the Republic of Belarus.
2. Republic of Kazakhstan
The need to establish the State Pharmacopoeia of the Republic of Kazakhstan was determined by Decree No. 2655 of the President of the Republic of Kazakhstan dated November 23, 1995, “On Medicinal Products”, having the force of law. Further development of this issue was determined by the Law of the Republic of Kazakhstan No. 522-II dated January 13, 2004, “On Medicinal Products”. In the absence of national pharmacopoeial requirements, an important step in the development of state quality control of medicinal products in the Republic of Kazakhstan was the recognition of leading pharmacopoeias (the European Pharmacopoeia, the United States Pharmacopeia, the British Pharmacopoeia and the German Homeopathic Pharmacopoeia) by Order No. 21 of the Pharmacy Committee of the Ministry of Health of the Republic of Kazakhstan dated February 11, 2004.
The State Pharmacopoeia of the Republic of Kazakhstan was established with state support in 2005–2008, approved and put into effect in 2008. The provisions establishing the status of the State Pharmacopoeia of the Republic of Kazakhstan are currently set out in the Code of the Republic of Kazakhstan No. 193-IV dated September 18, 2009, “On Public Health and the Healthcare System”.
The application of the standards of pharmacopoeias in force in the Republic of Kazakhstan is carried out in accordance with the adopted priority level. The first priority level is assigned to the State Pharmacopoeia of the Republic of Kazakhstan; in the absence of relevant pharmacopoeial monographs therein, the European Pharmacopoeia is applied (second priority level). The United States Pharmacopeia and the British Pharmacopoeia have the third priority level.
The State Pharmacopoeia of the Republic of Kazakhstan, 1st edition, was published in 2008–2009 in 2 volumes in the Kazakh and Russian languages. The first volume contains general pharmacopoeial monographs; the second volume includes 300 pharmacopoeial monographs on pharmaceutical substances, 26 pharmacopoeial monographs on medicinal plant raw materials, 77 pharmacopoeial monographs on medicinal products, and 15 pharmacopoeial monographs on vaccines for human use and human immunoglobulins. In addition to the harmonized texts, 100 national pharmacopoeial monographs on medicinal plant raw materials and medicinal products were included in the State Pharmacopoeia of the Republic of Kazakhstan.
Official permission to borrow texts from the European Pharmacopoeia was granted by its copyright holder – the European Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM).
For the purpose of harmonizing the State Pharmacopoeia of the Republic of Kazakhstan with the requirements of the United States Pharmacopeia, in July 2009 the Republic of Kazakhstan became an official observer, and in November 2010 – a member of the United States Pharmacopeial Convention (USP) with voting rights. In October 2010, an agreement was signed on harmonizing the State Pharmacopoeia of the Republic of Kazakhstan with the standards of the United States Pharmacopeia, allowing its texts to be borrowed for inclusion in national pharmacopoeial monographs through full and selective mechanisms. For the same purpose, in April 2014 an agreement was signed with the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), providing for the possibility of harmonizing the State Pharmacopoeia of the Republic of Kazakhstan with the standards of the British Pharmacopoeia.
Further development of the State Pharmacopoeia of the Republic of Kazakhstan is determined by the State Programme for Healthcare Development of the Republic of Kazakhstan “Salamatty Kazakhstan” for 2011–2015, approved by Decree No. 1113 of the President of the Republic of Kazakhstan dated November 29, 2010.
At present, the third volume of the State Pharmacopoeia of the Republic of Kazakhstan, harmonized with the requirements of the European Pharmacopoeia (EP 8.0–8.2), the United States Pharmacopeia (USP 37) and the British Pharmacopoeia (BP 2014), has been published. The edition contains 304 new general and specific pharmacopoeial monographs on pharmaceutical substances, medicinal plant raw materials, medicinal products, radiopharmaceutical products and starting materials for radiopharmaceutical products, homeopathic products, and medical devices.
The tests provided for in the development of pharmacopoeial monographs are performed in laboratories accredited as compliant with ST RK ISO/IEC 17025-2007 “General Requirements for the Competence of Testing and Calibration Laboratories”. At present, work is actively being carried out to obtain membership of these laboratories in the Network of Official Medicines Control Laboratories of the Council of Europe (OMCL GEON).
3. Russian Federation
There is continuity between the State Pharmacopoeia of the Russian Federation and the State Pharmacopoeia of the USSR, which, in turn, was the result of further development of the State Russian Pharmacopoeia. The history of publication of these pharmacopoeias collectively spans more than 200 years.
The provisions concerning the State Pharmacopoeia of the Russian Federation, which determine its official status, are enshrined in Federal Law No. 61-FZ dated April 12, 2010, “On the Circulation of Medicinal Products”.
At present, the State Pharmacopoeia of the Russian Federation, 12th edition (Part 1), 2007, is in force in the territory of the Russian Federation. However, due to the fact that it did not include the general pharmacopoeial articles in demand from the State Pharmacopoeia of the USSR, 11th edition (1986, 1989), and partly from the 10th edition (1968), all three of the above-mentioned editions are used in the Russian Federation. In the period between the publication of the State Pharmacopoeia of the USSR, 11th edition, and the State Pharmacopoeia of the Russian Federation, 12th edition (Part 1), individual general pharmacopoeial articles and pharmacopoeial articles, as well as amendments and supplements thereto, having legal force equal to that of the State Pharmacopoeia of the Russian Federation, were put into effect.
The Russian system of standardization of medicinal products is based on the following fundamental elements:
general pharmacopoeial articles;
pharmacopoeial articles;
pharmacopoeial reference standards.
The State Pharmacopoeia of the Russian Federation, 13th edition, the entry into force of which is scheduled for the near future, will contain 229 general pharmacopoeial articles on analytical methods, general methods, dosage forms, immunobiological medicinal products, medicinal plant raw materials and methods of their analysis. The requirements of almost all developed general pharmacopoeial articles are brought as close as possible to the requirements of analogous pharmacopoeial standards of leading foreign pharmacopoeias (the European, British and Japanese Pharmacopoeias and the United States Pharmacopeia).
As a result of the entry into force of these general pharmacopoeial articles (with the exception of several general pharmacopoeial articles that are not in demand), the general pharmacopoeial articles presented in the State Pharmacopoeia of the USSR, 10th and 11th editions, as well as in the State Pharmacopoeia of the Russian Federation, 12th edition, will be repealed.
In addition, more than 179 pharmacopoeial articles on medicinal products of synthetic, plant-based and biological origin will be included in the State Pharmacopoeia of the Russian Federation, 13th edition.
The State Pharmacopoeia of the Russian Federation, 13th edition, will contain all the main pharmacopoeial articles, including pharmacopoeial standards for a number of immunobiological medicinal products and methods for their analysis.
At present, the federal state budgetary institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation, represented by the Pharmacopoeia and International Cooperation Centre, is actively cooperating with leading foreign pharmacopoeias (the European, British and Japanese Pharmacopoeias and the United States Pharmacopeia) and the pharmacopoeias of the Member States. Representatives of the Russian Federation are included in the WHO working group on the development of the “Good Pharmacopoeial Practices” (GPhP) standard, established at the initiative of WHO within the framework of prospective harmonization of pharmacopoeial standards.
The tests provided for in the development of pharmacopoeial articles are performed at the Testing Centre for Quality Evaluation of Medicinal Products of the federal state budgetary institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation, 4 laboratories of which are certified as compliant with the international standard ISO/IEC 17025 and are associate members of the Network of Official Medicines Control Laboratories of the Council of Europe (OMCL GEON), and 2 laboratories of which, having undergone WHO prequalification, are recognized as compliant with the WHO standard “Good Practices for Pharmaceutical Quality Control Laboratories”.
4. Analysis of Initial Conditions for Harmonization of the Pharmacopoeias of the Member States and Development of the Pharmacopoeia of the Union
An analysis of the state and development prospects of the pharmacopoeial standards of the Member States makes it possible to identify the following as their strengths:
the availability of harmonization experience – in most cases, the pharmacopoeias of the Member States are harmonized with the requirements of the European Pharmacopoeia;
understanding of the role and mechanism of functioning of the pharmacopoeias of the Member States, and the need for continuous development and updating of the pharmacopoeial standards of the Member States;
understanding of the need for further harmonization of the pharmacopoeial standards of the Member States with the requirements of the world's leading pharmacopoeias (the European, British and Japanese Pharmacopoeias and the United States Pharmacopeia) and with each other;
availability of experience (knowledge, methodology, etc.) in the development and implementation of pharmacopoeial standards, acquired through regular participation in sessions of the European Pharmacopoeia Commission of the Council of Europe and in the process of establishing the pharmacopoeias of the Member States;
availability of international cooperation experience, participation in global pharmacopoeial activities, development and discussion of the WHO standard “Good Pharmacopoeial Practices” (GPhP), establishment of the Global Pharmacopoeia Index with the support of the United States Pharmacopeial Convention and the Chinese Pharmacopoeia Commission, and other international projects.
The weaknesses of the pharmacopoeial standards of the Member States are:
differences in the requirements of pharmacopoeial articles (monographs) of the pharmacopoeias of the Member States;
insufficient coverage of medicinal products, especially finished medicinal products, by pharmacopoeial articles (monographs) of the pharmacopoeias of the Member States;
lack of experience in multilateral harmonization of pharmacopoeial requirements of the Member States at the regional level as equal participants;
significant differences in the level of development and export orientation of the pharmaceutical industries of the Member States, which may affect the degree of stringency of the pharmacopoeial requirements of the Member States and complicate the harmonization process;
significant differences in the degree of harmonization of the pharmacopoeial requirements of the Member States with the world's leading pharmacopoeias (the European, British and Japanese Pharmacopoeias and the United States Pharmacopeia).
Within the framework of implementation of this Concept, it is envisaged that the action programme of the Member States and/or the authorized bodies of the Member States shall include:
support for the authorized bodies of the Member States in the field of circulation of medicinal products in order to ensure harmonization of the pharmacopoeias of the Member States;
training of highly qualified personnel in the fields of medicine and pharmacy and ensuring their participation in the development of national and harmonized regional pharmacopoeial requirements;
assistance in establishing testing laboratories equipped with modern analytical equipment and staffed with trained personnel for conducting experimental work on the preparation of pharmacopoeial articles (monographs) (their verification, validation, etc.);
involvement of international organizations, regulatory and pharmacopoeial authorities of other states in providing advisory and methodological assistance on issues relating to the development and harmonization of the requirements of pharmacopoeial articles (monographs).
IV. Stages and Timeframes for Implementation of the Concept
Taking into account that the development of general and specific pharmacopoeial articles (monographs) is a continuous process that is not limited in time, implementation of this Concept shall be carried out continuously.
At the same time, 2 stages of implementation of this Concept are identified.
The first stage provides for the development of harmonized general pharmacopoeial articles (monographs) of the Pharmacopoeia of the Union establishing requirements for:
methods for quality control of medicinal products and equipment necessary for conducting tests of the quality of medicinal products;
packaging materials;
reagents;
dosage forms;
pharmaceutical substances;
reference standards;
excipients used in the manufacture of medicinal products intended for circulation within the Union.
The development and, starting from 2016, entry into force of harmonized general pharmacopoeial articles (monographs) of the Pharmacopoeia of the Union shall be ensured by the authorized bodies of the Member States in the field of circulation of medicinal products.
The second stage provides for the development by the authorized bodies of the Member States in the field of circulation of medicinal products, on the basis of the Pharmacopoeial Committee of the Union, of harmonized specific pharmacopoeial articles (monographs) on pharmaceutical substances (including substances for pharmaceutical use in veterinary medicine), medicinal raw materials of natural origin (plant-based, animal-based), medicinal products and other medicinal products.
V. Approaches to Harmonization of the Pharmacopoeias of the Member States and Its Content
Approaches to harmonization of the pharmacopoeias of the Member States include:
introduction and application of the WHO standard “Good Pharmacopoeial Practices” (GPhP) at all levels of development, preparation and assessment of regulatory documentation for quality control of medicinal products;
gradual transition from the use of the pharmacopoeias of the Member States to the use of the Pharmacopoeia of the Union;
establishment of a single expert body – the Pharmacopoeial Committee of the Union – and centralized distribution by it of agreed pharmacopoeial articles (monographs) and guidelines on the quality of medicinal products.
In accordance with this Concept, the following shall be harmonized in the Member States:
terminology and measurement unit systems used;
pharmacopoeial requirements for equipment used in quality control of medicinal products;
pharmacopoeial requirements for physical, physicochemical, chemical, biological and other analytical methods;
pharmacopoeial requirements for the identification (verification of authenticity) of pharmaceutical substances;
pharmacopoeial requirements for tests for the content of impurities;
pharmacopoeial requirements for quantitative determination methods;
methods of biological testing and pharmacopoeial requirements for biological methods of quantitative determination;
pharmacopoeial requirements for pharmacognostic methods;
pharmacopoeial requirements for pharmaceutical-technological tests;
pharmacopoeial requirements for reagents, as well as materials and systems for the closure of medicinal product containers;
pharmacopoeial requirements for microbiological indicators;
pharmacopoeial requirements for dosage forms and groups of medicinal products;
pharmacopoeial requirements for homeopathic products;
pharmacopoeial requirements for pharmaceutical substances and preparations made from medicinal plant raw materials.
VI. Basic Principles and Provisions Ensuring Harmonization of the Pharmacopoeias of the Member States
The basic principles of harmonization of the pharmacopoeias of the Member States are:
continuity of the harmonization process;
transparency of the harmonization process;
compliance with copyright;
recognition of the right of the Member States to include harmonized pharmacopoeial articles (monographs) of the Pharmacopoeia of the Union in the pharmacopoeias of the Member States.
Harmonization of the pharmacopoeias of the Member States shall be carried out on the basis of the following provisions:
taking into account all types and mechanisms of harmonization of pharmacopoeial standards used in international practice;
taking into account the experience of formation of the pharmacopoeias of the Member States and their differences;
taking into account the requirements of the pharmacopoeias identified for the purposes of this Concept as principal pharmacopoeias (the European Pharmacopoeia, the British Pharmacopoeia, the United States Pharmacopeia), depending on their priority level;
interaction between the Pharmacopoeial Committee of the Union and the authorized bodies of the Member States in the field of circulation of medicinal products, including with regard to the provision of accredited testing laboratories of the Member States for verification of draft harmonized pharmacopoeial articles (monographs);
participation of representatives of the business community, scientific and public organizations, and other independent experts in the process of harmonization of the pharmacopoeias of the Member States;
development of international cooperation within the framework of the global process of harmonization of pharmacopoeial requirements.
VII. General Approach to Harmonization of the Pharmacopoeias of the Member States
1. Selection of the Harmonization Model
In international practice, the harmonization procedure is carried out using full (adoption) or selective (adaptation) mechanisms. The full mechanism involves copying a pharmacopoeial article (monograph) recognized as the reference one. When implementing the selective mechanism, it is permitted to establish more stringent or less stringent requirements for the quality of medicinal products compared with the requirements of the reference pharmacopoeial article (monograph).
There are two types of harmonization – retrospective and prospective. Retrospective harmonization applies to pharmacopoeial articles (monographs) included in pharmacopoeias. Prospective harmonization concerns testing methods (procedures) and medicinal products (excipients) that were not previously the subject of pharmacopoeial standardization.
The objects of harmonization shall include general sections and pharmacopoeial articles (monographs), as well as specific pharmacopoeial articles (monographs) of the pharmacopoeias of the Member States. Harmonization of pharmacopoeial articles (monographs) shall cover:
pharmaceutical substances;
medicinal raw materials of natural origin (plant-based, animal-based);
dosage forms;
medicinal products;
biological products;
tests (physical, physicochemical, chemical, biological, pharmaceutical-technological, etc.);
testing methods (procedures);
permissible limits (acceptance criteria) established for quality indicators of medicinal products and testing methods (procedures).
In the European Pharmacopoeia, requirements for medicinal products are regulated by general monographs rather than specific monographs. Unlike it, other pharmacopoeias (the British Pharmacopoeia and the United States Pharmacopeia), in addition to general monographs, also provide specific monographs for medicinal products.
This Concept proceeds from the need to regulate harmonized pharmacopoeial requirements of the Pharmacopoeia of the Union both for pharmaceutical substances and for the corresponding medicinal products. Harmonized pharmacopoeial articles (monographs) for medicinal products may, where necessary, be harmonized with the British Pharmacopoeia and the United States Pharmacopeia.
Differences in the requirements of the principal pharmacopoeias determine the need to establish priority levels for the principal pharmacopoeias in the harmonization process. The first priority level provides for the selection of the reference pharmacopoeia. The second priority level provides for the application of another pharmacopoeia in the absence of a corresponding pharmacopoeial article (monograph) in the reference pharmacopoeia.
For the purpose of developing a model for harmonization of the pharmacopoeias of the Member States, it is appropriate to identify the following cases:
the object of harmonization is regulated by the reference pharmacopoeia of the first level;
the object of harmonization is regulated by second-level pharmacopoeias;
the object of harmonization is not regulated by any pharmacopoeia of the first or second level.
In the first two cases, harmonization may be carried out using either the full or the selective mechanism. The selective mechanism provides for partial borrowing of individual pharmacopoeial provisions, or testing methods (procedures), or permissible limits (acceptance criteria), etc. In the event of modification of pharmacopoeial testing methods (procedures), their verification and validation shall be carried out in accordance with the accepted pharmacopoeial requirements of the Pharmacopoeia of the Union.
The full harmonization mechanism does not require the development of a harmonized pharmacopoeial article (monograph); it is sufficient merely to indicate a reference to the relevant pharmacopoeia that serves as the source of borrowing. When using the selective mechanism, a harmonized pharmacopoeial article (monograph) shall be developed for each object of harmonization to which it has been applied, with an indication of the source of borrowing.
If the object of harmonization is not regulated by any pharmacopoeia of the first or second level, the development of harmonized pharmacopoeial articles (monographs) is mandatory. In this case, the type of harmonization of pharmacopoeial requirements may be either retrospective or prospective. Retrospective harmonization is possible if the object of harmonization is described in the pharmacopoeias of the Member States. In the absence of a corresponding pharmacopoeial article (monograph) in the pharmacopoeias of the Member States, prospective harmonization shall be carried out on the basis of the quality specifications of the manufacturer of the medicinal product (excipient).
In accordance with international norms and principles in the field of circulation of medicinal products, pharmacopoeial articles (monographs) shall be considered harmonized if testing of medicinal products (excipients) using harmonized methods produces the same results and a decision is made regarding their acceptability.
2. Priority Levels of the Principal Pharmacopoeias, Taking into Account the Requirements of Which Harmonization of Pharmacopoeial Articles (Monographs) of the Pharmacopoeias of the Member States Will Be Carried Out
Within the framework of harmonization of the pharmacopoeias of the Member States, the following shall be recognized as principal pharmacopoeias:
the European Pharmacopoeia;
the British Pharmacopoeia;
the United States Pharmacopeia.
It is appropriate to recognize the European Pharmacopoeia as the reference pharmacopoeia (the principal pharmacopoeia of the first level), in view of the full harmonization of the pharmacopoeias of the Republic of Belarus and the Republic of Kazakhstan with it, as well as the use of the pharmacopoeial articles (monographs) of this Pharmacopoeia in their entirety by the Republic of Armenia.
The British Pharmacopoeia and the United States Pharmacopeia have the status of second-level pharmacopoeias. At the same time, with regard to veterinary medicinal products, the British Pharmacopoeia has priority in the harmonization of texts.
3. General Procedure for Harmonization of the Pharmacopoeias of the Member States
The process of developing and approving harmonized pharmacopoeial articles (monographs) shall be carried out in accordance with the procedure for harmonization of the pharmacopoeias of the Member States determined by the Pharmacopoeial Committee of the Union.
The Agreement on Common Principles and Rules for the Circulation of Medicinal Products within the Eurasian Economic Union dated December 23, 2014, provides for the establishment of the Pharmacopoeial Committee of the Union, consisting of specialists recommended by each of the Member States and the Eurasian Economic Commission, for the purposes of harmonization of pharmacopoeial articles (monographs). The main tasks and powers of the Pharmacopoeial Committee of the Union are established by the Regulation on the Pharmacopoeial Committee of the Eurasian Economic Union, approved by the Eurasian Economic Commission.
The selection of the harmonization procedure shall be carried out by the Pharmacopoeial Committee of the Union and shall include the following stages:
submission by one of the authorized bodies of a Member State in the field of circulation of medicinal products to the Pharmacopoeial Committee of the Union of an application regarding the need to develop a harmonized pharmacopoeial article (monograph), update or amend a pharmacopoeial article (monograph), together with the relevant justification;
consideration of the said application by the Pharmacopoeial Committee of the Union and adoption of an appropriate decision on the advisability of developing a harmonized pharmacopoeial article (monograph), updating or amending a pharmacopoeial article (monograph);
determination by the Pharmacopoeial Committee of the Union of the authorized body and/or organization of the Member State that will develop the draft harmonized pharmacopoeial article (monograph), update or amendments to the pharmacopoeial article (monograph) (hereinafter referred to as the developer), in the event that the Pharmacopoeial Committee of the Union adopts a decision on the advisability of developing the relevant harmonized pharmacopoeial article (monograph), updating or amending the pharmacopoeial article (monograph);
submission by the responsible developer to the secretariat of the Pharmacopoeial Committee of the Union of the draft harmonized pharmacopoeial article (monograph), update or amendments to the pharmacopoeial article (monograph), an explanatory note with the relevant justification and other necessary documents;
consideration and discussion by the Pharmacopoeial Committee of the Union of the draft harmonized pharmacopoeial article (monograph), update or amendments to the pharmacopoeial article (monograph), the explanatory note with the relevant justification and the documents attached to the draft, as well as, where necessary, consideration and discussion of this draft, the explanatory note with the relevant justification and the documents attached thereto by a specialized expert group under the Pharmacopoeial Committee of the Union;
verification of the draft harmonized pharmacopoeial article (monograph) in accredited testing laboratories of the Member States designated by the Pharmacopoeial Committee of the Union for these purposes (where necessary, especially in the case of prospective harmonization);
revision (where necessary) by the responsible developer of the draft harmonized pharmacopoeial article (monograph) on the basis of recommendations received at meetings of specialized expert groups under the Pharmacopoeial Committee of the Union;
repeated consideration of the draft harmonized pharmacopoeial article (monograph) by the Pharmacopoeial Committee of the Union (where necessary);
adoption of a decision to publish the draft harmonized pharmacopoeial article (monograph) in specialized publications of the Member States and on the official website of the Union on the Internet for public discussion;
consideration by the specialized expert group under the Pharmacopoeial Committee of the Union of comments received as a result of public discussion (if any), and introduction of the necessary corrections by the responsible developer;
approval of the draft harmonized pharmacopoeial article (monograph) by the specialized expert group under the Pharmacopoeial Committee of the Union and its subsequent approval by the Pharmacopoeial Committee of the Union;
approval by the Chairman of the Pharmacopoeial Committee of the Union, based on the results of consideration at a meeting of the Pharmacopoeial Committee of the Union, of the approved harmonized pharmacopoeial article (monograph), and preparation of a draft decision of the Eurasian Economic Commission on the inclusion of this pharmacopoeial article (monograph) or a group of pharmacopoeial articles (monographs) in the Pharmacopoeia of the Union;
publication of a volume of the Pharmacopoeia of the Union or a supplement to a volume of the Pharmacopoeia of the Union, including:
layout of the texts of pharmacopoeial articles (monographs) of the Pharmacopoeia of the Union;
scientific editing of the texts of pharmacopoeial articles (monographs) of the Pharmacopoeia of the Union;
proofreading of the texts of pharmacopoeial articles (monographs) of the Pharmacopoeia of the Union;
publication of a volume of the Pharmacopoeia of the Union or a supplement to a volume of the Pharmacopoeia of the Union.
4. Principles for the Development of Harmonized Pharmacopoeial Articles (Monographs)
In order to ensure uniformity of the principles for developing harmonized pharmacopoeial articles (monographs), the Pharmacopoeial Committee of the Union shall approve guidelines for the development and harmonization of pharmacopoeial articles (monographs).
The guidelines for the development and harmonization of pharmacopoeial articles (monographs) shall be prepared taking into account the provisions of the Technical Guide for the Development of Monographs adopted by the European Pharmacopoeia Commission of the Council of Europe, the WHO standard “Good Pharmacopoeial Practices” (GPhP), and the relevant guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
5. Pharmacopoeia of the Union
Harmonized general pharmacopoeial articles (monographs) establishing requirements for methods of quality control of medicinal products and equipment necessary for conducting tests of the quality of medicinal products, packaging materials, reagents, dosage forms, pharmaceutical substances, reference standards, and excipients used in the manufacture of medicinal products intended for circulation within the Union shall constitute the first volume of the Pharmacopoeia of the Union.
Harmonized specific pharmacopoeial articles (monographs) on pharmaceutical substances (including pharmaceutical substances for veterinary use), medicinal raw materials of natural origin (plant-based, animal-based), medicinal products and other medicinal products shall constitute the subsequent volumes of the Pharmacopoeia of the Union.
Harmonized pharmacopoeial articles (monographs) on veterinary medicinal products shall be included in a separate volume of the Pharmacopoeia of the Union (in cases where they differ from pharmacopoeial articles (monographs) on medicinal products for human use).
Harmonized general and specific pharmacopoeial articles (monographs) that are not included in the next edition of the Pharmacopoeia of the Union may be published in the form of supplements.
The Pharmacopoeia of the Union shall have the first priority level in the harmonization process in relation to the principal pharmacopoeias with whose requirements it has been harmonized.
The requirements of the Pharmacopoeia of the Union shall be complied with in the circulation of medicinal products within the Union.
In order to ensure the proper functioning of the common market for medicinal products within the Union, the Pharmacopoeia of the Union must be updated at least once every 5 years.
The organization of preparation of the edition of the Pharmacopoeia of the Union and its subsequent regular updating shall be ensured by the Eurasian Economic Commission.
6. Reference Standards Necessary to Ensure Harmonized Pharmacopoeial Articles (Monographs) of the Pharmacopoeia of the Union
A list of reference standards shall be formed to ensure the harmonized pharmacopoeial articles (monographs) of the Pharmacopoeia of the Union, and the procedure for maintaining this list shall be determined by the Pharmacopoeial Committee of the Union.
Suitable reference standards of the Pharmacopoeia of the Union, the pharmacopoeias of the Member States and the principal pharmacopoeias may be used as reference standards.
Constitution Law Code Normative Decree Order Decision Resolution Advocate Almaty Lawyer Legal Service Legal Consultation Civil Criminal Administrative Cases and Disputes Defense Arbitration Legal Company Kazakhstan Law Office Court Cases Declaration Decree Order Resolution Decision Report Conclusion Application Conclusion Convention Contract Memorandum Methodology Norms Note Rules Programme Charter Article Commentary Resolution Regulations Protocol Draft Programme Rules Messages